Menu Search
Equities

AnGes Inc

4563:TYO

AnGes Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (JPY)73.00
  • Today's Change-5.00 / -6.41%
  • Shares traded70.80m
  • 1 Year change-23.96%
  • Beta1.6749
Data delayed at least 20 minutes, as of Sep 20 2024 07:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in JPYIncome statement in JPYView more

Year on year AnGes Inc grew revenues 128.13% from 67.06m to 152.99m while net income improved from a loss of 14.71bn to a smaller loss of 7.44bn.
Gross margin38.79%
Net profit margin-1,359.35%
Operating margin-2,931.20%
Return on assets-18.95%
Return on equity-22.89%
Return on investment-22.32%
More ▼

Cash flow in JPYView more

In 2023, cash reserves at AnGes Inc fell by 6.88bn. Cash Flow from Financing totalled 2.04bn or 1,331.15% of revenues. In addition the company used 8.75bn for operations while cash used for investing totalled 356.65m.
Cash flow per share-17.86
Price/Cash flow per share--
Book value per share107.33
Tangible book value per share10.67
More ▼

Balance sheet in JPYView more

AnGes Inc has little financial risk as the capital structure does not rely on leverage.
Current ratio1.86
Quick ratio1.19
Total debt/total equity0.0132
Total debt/total capital0.013
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.